NeuroPace reports record 2023 revenue $65.4M (+44% YoY); guides 2024 revenue $73M-$77M

NeuroPace Inc

Record FY 2023 revenue $65.4M (+44% YoY); Q4 revenue $18.0M (+41% YoY). Net loss improved to $33.0M from $47.1M.
Gross margin improved to 73.6% (FY) from 71.4%; Q4 75.2% vs 68.8%. Cash burn reduced to $3.4M in Q4.
FY 2024 guidance: revenue $73M-$77M (+12-18%), gross margin 72-74%, operating expenses $80M-$84M.
NAUTILUS study for generalized epilepsy completed enrollment and implants for FDA submission; Project CARE pilot initiated.
Cash position $66.5M, long-term debt $57.0M; stock-based comp ~$9.6M in 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NeuroPace Inc reported fourth quarter and full year ended December 31, 2023 results: revenue $18.0 million, net income $6.2 million. Guidance initiated.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $18.0 million
Net income: $6.2 million
Guidance: initiated
Result: reported results

Exact text from the filing

NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million Revenue increased to $18.0 million in Q4 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001528287-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.